<DOC>
	<DOCNO>NCT00505375</DOCNO>
	<brief_summary>The purpose study determine whether treatment CTLA4-Ig ( Abatacept ) individual new onset T1DM improve insulin secretion ( C-peptide production ) compare placebo .</brief_summary>
	<brief_title>Intravenous CTLA4-lg Treatment Recent Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Type 1 diabetes mellitus ( T1DM ) T-cell mediate autoimmune disease insulin-producing beta cell completely near completely destroy result life-long dependence exogenous insulin . CTLA4-Ig ( Abatacept ) inhibit crucial stimulatory pathway activation T cell . By mechanism , drug think arrest slow T cell mediate autoimmune destruction beta-cells preserve function . At time clinical onset T1DM , significant amount insulin produce beta cell destroy , many 10-20 % still capable insulin production . By use CTLA4-Ig close onset T1DM , hope arrest slow autoimmune destruction beta-cells extend endogenous insulin production . CTLA4-Ig regulates T cell function deplete T cell . Therefore , safety profile appear well immunosuppressive agent . Eligible participant randomize experimental control group . The experimental group receive intravenous infusion CTLA-4 Ig . The first infusion occur time randomization , follow another infusion 2 4 week later . Subsequent infusion give monthly two year treatment phase study . There total 27 infusion treatment phase study . Participants control group receive intravenous infusion placebo accord schedule outline . Both group receive standard intensive diabetes treatment insulin dietary management . All participant randomize study see study site monthly 24 month every 6 month additional 2 year . Participants undergo assessment insulin production , immunologic status , overall health well diabetes care .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Age 645 2 . Within 3 month ( 100 day ) diagnosis T1DM base ADA criterion 3 . At least one diabetesrelated autoantibody 4 . Stimulated Cpeptide level &gt; 0.2 pmol/ml MMTT conduct 21 day diagnosis T1DM within 37 day randomization 5 . At least three month last live immunization receive willing forgo live vaccination three month follow last dose study treatment 1 . Immunodeficiency , chronic lymphopenia , active infection , positive PPD result history malignancy 2 . Serologic evidence current past HIV , Hepatitis B C 3 . Pregnancy , lactation , intention pregnancy study 4 . Current use immunosuppressive agent , medication know influence glucose tolerance glycemic control 5 . Current participation another T1DM treatment study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CTLA4-Ig</keyword>
	<keyword>Abatacept</keyword>
	<keyword>Beta-cell function</keyword>
	<keyword>T-cells</keyword>
	<keyword>DPT-1</keyword>
	<keyword>treatment</keyword>
	<keyword>treatment type 1 diabetes</keyword>
	<keyword>new onset type 1 diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>T1D</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>Type 1 diabetes TrialNet</keyword>
	<keyword>TrialNet</keyword>
</DOC>